Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

Blood (2024) 144 (Supplement 1): 1787.

https://doi.org/10.1182/blood-2024-197898

Published: 2024

Journal Articles

Identifying 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA and Treatment Response in Multiple Myeloma with a Multi-Step Machine Learning Approach

Bei Wang, Benjamin A Derman, Zhou Zhang, Krissana Kowitwanich, John F. Cursio, Daniel Appelbaum, Chuan He, Wei Zhang, Andrzej J Jakubowiak, Brian Chiu

Blood (2024) 144 (Supplement 1): 3336.

https://doi.org/10.1182/blood-2024-204305

Published: 2024

Journal Articles

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Blood (2008) 112 (11): 2293.

https://doi.org/10.1182/blood.V112.11.2293.2293

Published: 2008

Journal Articles

Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.

Charles L. Bennett, MD, PhD, MPP, Thanh Ha Luu, BA, Anaadriana Zakarija, MD, Hau C. Kwaan, MD, PhD, Nicholas Bandarenko, MD, Dilip K. Pandey, MBBS, MS, PhD, John F. Cursio, MS, June M. McKoy, MD, JD, MPH, Charlie Buffie, BA, Jeffrey L. Winters, MD, Thomas L. Ortel, MD, Ravindra Sarode, MD, X. Long Zheng, MD, PhD, Thomas J. Raife, MD, Masanori Matsumoto, MD, PhD, Yoshihiro Fujimura, MD, PhD, Gail A. Rock, MD, PhD

Blood (2007) 110 (11): 2088.

https://doi.org/10.1182/blood.V110.11.2088.2088

Published: 2007

Journal Articles

Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group.

Elizabeth A. Richey, BA, Charles L. Bennett, MD, PhD, MPP, Hau C. Kwaan, MD, PhD, Anaadriana Zakarija, MD, MSCI, Nicholas Banderanko, MD, Dilip K. Pandey, MD, PhD, June M. McKoy, MD, JD, MPH, Paul R. Yarnold, PhD, Dennis W. Raisch, PhD, Jeffrey L. Winters, MD, Thomas J. Raife, MD, John F. Cursio, MS, Matthew J. Fisher, Thomas L. Ortel, MD, PhD, Martin S. Tallman, MD, Masanori Matsumoto, MD, PhD, Yoshihiro Fujimura, MD, PhD, Joel L. Moake, MD

Blood (2007) 110 (11): 2089.

https://doi.org/10.1182/blood.V110.11.2089.2089

Published: 2007

Journal Articles

Distinct Clinical Syndromes Are Defined by ADAMTS13 Activity in Idiopathic TTP: Results of the SERF-TTP Study.

Anaadriana Zakarija, MD, Hau C. Kwaan, MD PhD, Nicholas Banderanko, MD, Dilip K. Pandey, MD PhD, John F. Cursio, MS, Ivy M. Weiss, BA, Thanh Ha Luu, BA, Jeffrey L. Winters, MD, Thomas L. Ortel, MD PhD, Thomas J. Raife, MD, Ravindra Sarode, MD, Charles L. Bennett, MD PhD MPP

Blood (2007) 110 (11): 1320.

https://doi.org/10.1182/blood.V110.11.1320.1320

Published: 2007

NARROW

Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

Identifying 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA and Treatment Response in Multiple Myeloma with a Multi-Step Machine Learning Approach

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.

Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group.

Distinct Clinical Syndromes Are Defined by ADAMTS13 Activity in Idiopathic TTP: Results of the SERF-TTP Study.

Email alerts

ASH Publications

American Society of Hematology

Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

Identifying 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA and Treatment Response in Multiple Myeloma with a Multi-Step Machine Learning Approach

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.

Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group.

Distinct Clinical Syndromes Are Defined by ADAMTS13 Activity in Idiopathic TTP: Results of the SERF-TTP Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only